Skip to main content

David Moreno Martinez

Institutions of which they are part

Systemic Diseases
Vall Hebron Institut de Recerca
David Moreno Martinez

David Moreno Martinez

David Moreno Martinez

Institutions of which they are part

Systemic Diseases
Vall Hebron Institut de Recerca

Projects

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 31/10/2025

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Daniela Samaniego Toro, Laura Castillo Ribelles
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, José Antonio Arranz Amo, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Related news

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

The study showing how thrombocytopenia increases the risk of thrombosis in patients with antiphospholipid syndrome has been considered the best paper published in 2021.

Related professionals

Immaculada Creus Gonzalez

Immaculada Creus Gonzalez

Research technician
Read more
Marta Miarons Font

Marta Miarons Font

Head of group
Basic, Translational and Clinical Pharmacy Research
Read more
Alvaro Garcia Tornel Garcia Camba

Alvaro Garcia Tornel Garcia Camba

Senior researcher
Stroke research
Read more
Ferran Polo Torres

Ferran Polo Torres

Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.